Clinical Trial Update: Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating sunitinib malate or valproic acid to prevent metastasis in high-risk uveal melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Melanoma
• Ciliary Body Melanoma
• Intraocular Melanoma
• Iris Melanoma
• Uveal Melanoma

Drugs mentioned

• Sunitinib malate (sunitinib malate)
• VALPROIC ACID (Valproic acid)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Status: ACTIVE_NOT_RECRUITING